Expansion of NK and DC cells in vivo mediating immune response
US12011460B2 · kind B2 · utility
0Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2019 |
| Grant date | Jun 18, 2024 |
| Priority date | — |
| Expiry date | May 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2506/1315
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It is provided a method of expanding dendritic (DC) cells and/or natural killer (NK) cells in vivo in a patient comprising the steps of producing a graft of stem and progenitor cells cultured with UM171 or analogues therefrom and expanded before being administered to the patient. The expansion or increase in dendritic (DC) cells and/or natural killer (NK) cells population in the patient results in an increase immune response reducing transplant related mortality (TRM), severe graft-versus-host disease (GVHD), relapse, and/or severe viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.